QQ客服 官方微博 反馈留言

	Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
	Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Armstrong, Anne; Bannister, Wendy; Conte, Pierfranco
刊名	CANCER RESEARCH
	2018
卷号	78期号:4
ISSN号	0008-5472
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3534587
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Robson, Mark,Im, Seock-Ah,Senkus, Elzbieta,et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD[J]. CANCER RESEARCH,2018,78(4).
APA	Robson, Mark.,Im, Seock-Ah.,Senkus, Elzbieta.,Xu, Binghe.,Masuda, Norikazu.,...&Goessl, Carsten.(2018).Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.CANCER RESEARCH,78(4).
MLA	Robson, Mark,et al."Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD".CANCER RESEARCH 78.4(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。